Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Carcinoma, Non-Small-Cell Lung 2 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumors 1 Sarcoma 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neoplastic Cells, Circulating 1 Lung Neoplasms 1 Liposarcoma 1 Histiocytoma, Malignant Fibrous 1 Fallopian Tube Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Dermatofibrosarcoma 1 Colorectal Neoplasms 1 Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Paclitaxel 328 Carboplatin 323 Bevacizumab 171 Gemcitabine 106 liposomal doxorubicin 104 pembrolizumab 101 Cyclophosphamide 96 Topotecan 94 olaparib 92 Cisplatin 92 niraparib 69 Docetaxel 57 Taxes 52 Doxorubicin 51 Drug Therapy 45 fludarabine 40 Filgrastim 39 Nivolumab 37 Magnetic Resonance Spectroscopy 34 Surveys and Questionnaires 33 Specimen Handling 33 Etoposide 32 Hyperthermic Intraperitoneal Chemotherapy 31 Blood Specimen Collection 29 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Cytoreduction Surgical Procedures 25 Albumin-Bound Paclitaxel 25 durvalumab 24

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Neoplasms × Histamine H2 Antagonists × Clear all

NCT06824467 2026-05-29

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡